Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Pfizer files suit...

    Pfizer files suit against Johnson and Johnson over Remicade

    Written by Ruby Khatun Khatun Published On 2017-09-23T13:58:24+05:30  |  Updated On 23 Sept 2017 1:58 PM IST
    Pfizer files suit against Johnson and Johnson over Remicade


    Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson and Johnson, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer’s new biosimilar.


    Pfizer said in the suit that J&J is offering discounts on its Remicade treatment in exchange for essentially excluding Pfizer’s drug from insurance coverage, keeping it out of the hands of patients.


    J&J said in an e-mailed statement that the lawsuit was without merit and that the company is competing on value and price.


    “To date, Pfizer has failed to demonstrate sufficient value to patients, providers, payers, and employers,” said Scott White, President of Janssen Biotech Inc, a unit of J&J.



    J&J signed exclusionary contracts with health insurers, hospitals, and doctor groups after U.S. regulators approved it as a reasonable substitute for Remicade in 2016, Pfizer said.

    The contracts with insurers - including UnitedHealth Group, Anthem Inc, Aetna Inc and Cigna Corp - covered about 70 percent of the commercially insured patients in the United States, the lawsuit said.


    Both Aetna and Anthem declined to comment. Other U.S. insurers contacted for this story did not have an immediate comment.


    Remicade is an infused treatment for chronic autoimmune disorders and costs about $4,000 per dose, or $26,000 a year, Pfizer said in the suit. Its Inflectra rival is priced 19 percent lower than that list price.


    But Pfizer said it has not been able to reach customers because of J&J’s anticompetitive actions. The suit comes at a time when insurers, consumers, and the U.S. government have pushed for lower drug prices, saying double-digit annual price increases are unsustainable.


    Biosimilars are intended to be lower cost alternatives to expensive biotech medicines. But because they are made from living cells and it is not possible to make an exact copy of the branded medicine, they are not automatically substituted for the existing branded drug the way a generic drug would be.


    Pfizer said in the lawsuit that J&J’s contracts with many insurers exclusively pay for Remicade and only pay for Inflectra in limited cases where patients “fail first” on Remicade.


    In return, Pfizer said, J&J pays after-market rebates on both new and existing customers’ Remicade purchases. To make up for the J&J rebates and discounts on this large base of old and new customers, Pfizer said it would need to price Inflectra below its own average variable cost.


    Pfizer shares were up 1.3 percent, or 45 cents, at $35.90 and J&J shares fell 1.6 percent, or $2.10, to $133.11.


    The case was filed in the U.S. District Court for the Eastern District of Pennsylvania.




    (Reporting by Caroline Humer in New York and Divya Grover in Bengaluru; editing by Sriraj Kalluvila, Nick Zieminski, and G Crosse)





    anticompetitivebiosimilarfilesJ&JJanssen Biotech IncJohnson and JohnsonlawsuitPfizerRemicaderheumatoid arthritisScott White
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok